Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tezepelumab (Primary)
Indications Eosinophilic oesophagitis
Focus Registrational; Therapeutic Use
Acronyms CROSSING
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

20 Oct 2026 Results presented in the Amgen media release.
20 Oct 2026 According to AstraZeneca media release, trial were presented in a late-breaking oral presentation at United European Gastroenterology Week 2026.
20 Oct 2026 Results published in the AstraZeneca media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com